Evidence map›Paper›PMID 31133031›Full record

ReviewVirology journal2019

Coronavirus envelope protein: current knowledge.

Dewald Schoeman, Burtram C Fielding

Registry-linked trialOpen access · goldAbstract readReview
In one paragraph

Review in Virology journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05618483 (Clinical Efficacy of Xylitol Based Nasal Spray for the Treatment of Mild COVID-19 Infection), which is not on this map. Cited by 944 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
944citing papers in PubMed, 2 pooled it
255.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05618483 naunknown statusnot on this mapstarted 2022, after this paper: background citation

Clinical Efficacy of Xylitol Based Nasal Spray for the Treatment of Mild COVID-19 Infection

TypeinterventionalSponsorXlear, IncRan2022 to 2024Enrolled80ConditionsRespiratory Viral InfectionArmsNasal Spray
3 · Its place in the literature

Who cites it

944 citing papers in PubMed, 2 syntheses or guidelines pooled it, 2,169 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

884 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Dewald SchoemanMolecular Biology and Virology Research Laboratory, Department of Medical Biosciences, University of the Western Cape, Cape Town, South Africa.
Burtram C FieldingMolecular Biology and Virology Research Laboratory, Department of Medical Biosciences, University of the Western Cape, Cape Town, South Africa. bfielding@uwc.ac.za.ORCID 0000-0002-1873-3363
University of the Western Cape · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCoronaviruses (CoVs) primarily cause enzootic infections in birds and mammals but, in the last few decades, have shown to be capable of infecting humans as well. The outbreak of severe acute respiratory syndrome (SARS) in 2003 and, more recently, Middle-East respiratory syndrome (MERS) has demonstrated the lethality of CoVs when they cross the species barrier and infect humans. A renewed interest in coronaviral research has led to the discovery of several novel human CoVs and since then much progress has been made in understanding the CoV life cycle. The CoV envelope (E) protein is a small, integral membrane protein involved in several aspects of the virus' life cycle, such as assembly, budding, envelope formation, and pathogenesis. Recent studies have expanded on its structural motifs and topology, its functions as an ion-channelling viroporin, and its interactions with both other CoV proteins and host cell proteins. MAIN BODY: This review aims to establish the current knowledge on CoV E by highlighting the recent progress that has been made and comparing it to previous knowledge. It also compares E to other viral proteins of a similar nature to speculate the relevance of these new findings. Good progress has been made but much still remains unknown and this review has identified some gaps in the current knowledge and made suggestions for consideration in future research.

conclusionsThe most progress has been made on SARS-CoV E, highlighting specific structural requirements for its functions in the CoV life cycle as well as mechanisms behind its pathogenesis. Data shows that E is involved in critical aspects of the viral life cycle and that CoVs lacking E make promising vaccine candidates. The high mortality rate of certain CoVs, along with their ease of transmission, underpins the need for more research into CoV molecular biology which can aid in the production of effective anti-coronaviral agents for both human CoVs and enzootic CoVs.

Indexed as

AnimalsCoronavirusCoronavirus InfectionsHumansSevere Acute Respiratory SyndromeSevere acute respiratory syndrome-related coronavirusViral Envelope ProteinsZoonosesViral Envelope ProteinsAssemblyBuddingCoronavirusEnvelope proteinTopologyViroporin

Identifiers

PMID31133031
PMCPMC6537279
OpenAlexW2947642275

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.